The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Biologic medications help reduce inflammation in ulcerative colitis. If you're new to biologics, infliximab might be your first option for ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Drug clearance was associated with a reduction in disease activity in children who responded to ...

Please provide your email address to receive an email when new articles are posted on . In a multicenter, open-label trial, researchers investigated the outcomes of discontinued infliximab use in ...

Centocor Ortho Biotech announced results from its Phase 3 study of Remicade (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC). This ...

A new study found cyclosporine was no more effective than infliximab in patients with acute, severe ulcerative colitis refractory to intravenous steroids, according to a report by Internal Medicine ...

WASHINGTON, DC, May 23, 2007— Findings presented today at Digestive Disease Week® 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with ...

Ciclosporin and infliximab are used as rescue therapies for the treatment of severe steroid-refractory ulcerative colitis. Now, an open-label, head-to-head randomized controlled trial has demonstrated ...